Cancer Research in Switzerland - Krebsliga Schweiz

More documents

Recommendations

Info

60 Gönczy Pierre | KLS 02024022007 | CHF 335,100.– UPGON, Institut suisse de recherche expérimentale sur le cancer (ISREC), Faculté des sciences de la vie, EPF de Lausanne, Lausanne Mechanisms of centrosome duplication in C. elegans and human cells: From model organism towards therapeutic opportunities Grassi Fabio | OCS 01933082006 | CHF 174,300.– Istituto di ricerca biomedica (IRB), Bellinzona Sinergy between oncogenic Notch and pre-T cell receptor (pre-TCR) signalling microdomains in leukemogenesis Hall Michael N. | KLS 01991022007 | CHF 350,500.– Departement Biozentrum, Universität Basel, Basel Proteomic analysis of the cancer-promoting mTOR pathway Heim Markus Hermann | OCS 02192022008 | CHF 245,200.– Klinik für Gastroenterologie und Hepatologie, Universitätsspital Basel, Basel Hepatocarcinogenesis in chronic hepatitis C Hemmings Brian A. | OCS 01667022005 | CHF 271,350.– Friedrich Miescher Institut für biomedizinische Forschung (FMI), Basel Role of protein kinase B (PKB/Akt) in cell transformation and cancer Hemmings Brian A. | OCS 01942082006 | CHF 275,400.– Friedrich Miescher Institut für biomedizinische Forschung (FMI), Basel The role of human protein kinase NDR in cell morphogenesis, cell division, growth control and cancer Herr Winship | OCS 02047022007 | CHF 301,900.– Centre intégratif de génomique (CIG), Faculté de biologie et de médecine, Université de Lausanne, Lausanne HCF-1 regulation of genomic stability during cell division Hübscher Ulrich | OCS 01996022007 | CHF 251,800.– Institut für Veterinärbiochemie und Molekularbiologie, Universität Zürich, Zürich Repair of oxidation damages in DNA: DNA synthesis over lesions by posttranslationally modified human DNA polymerase � Huelsken Joerg | OCS 01838022006 | CHF 336,600.– UPHUE, Institut suisse de recherche expérimentale sur le cancer (ISREC), Faculté des sciences de la vie, EPF de Lausanne, Lausanne Role of inflammation in Wnt-mediated tumorigenesis Hynes Nancy | KLS 02187022008 | CHF 47,600.– Friedrich Miescher Institut für biomedizinische Forschung (FMI), Basel Characterisation of the role of PN-1 in breast cancer and its potential as a therapeutic target Janscak Pavel | OCS 01730082005 | CHF 221,500.– Institut für molekulare Krebsforschung, Universität Zürich, Zürich Study of the role of the human mismatch repair system in telomere metabolism Krek Wilhelm | OCS 01787082005 | CHF 335,500.– Institut für Zellbiologie, ETH Zürich, Zürich Roles of F-box protein Skp2-based E3 ubiquitin protein ligases in cell cycle control and neoplastic signalling Continuation in the project: Krek Wilhelm | KFS 02690082010 | CHF 226,000.– Institut für Zellbiologie, ETH Zürich, Zürich Roles of the URI oncoprotein in B-RAF-signaling and melanoma cancer cell proliferation Duration: 01.02.2011 – 01.02.2013 Lange Norbert | OCS 01948082006 | CHF 163,200.– Laboratoire de pharmaceutique et de biopharmacie, Section des sciences pharmaceutiques, Université de Genève, Genève Synthesis and evaluation of new water soluble polymeric photosensitizer prodrugs for photodynamic therapy MacDonald Hugh Robson | OCS 01863022006 | CHF 346,300.– Centre Ludwig de recherche sur le cancer, Epalinges The role of proto-oncogenes in hematopoietic and cancer stem cells
Moradpour Darius | OCS 01762082005 | CHF 250,700.– Division de gastroentérologie et d’hépatologie, Centre hospitalier universitaire vaudois (CHUV), Lausanne Development of a model system to study coinfection by hepatitis B and C viruses – the major causes of hepatocellular carcinoma Müller Anne | OCS 02099082007 | CHF 191,500.– Institut für molekulare Krebsforschung, Universität Zürich, Zürich The molecular pathogenesis of Helicobacter pylori-induced mucosa-associated lymphoid tissue (MALT) lymphoma in an animal model: Analysis of the role of tumor infiltrating accessory cells in vivo and ex vivo and of the specificity of tumor immunoglobulin Continuation in the project: Müller Anne | KFS 02640082010 | CHF 293,700.– Institut für molekulare Krebsforschung, Universität Zürich, Zürich The molecular pathogenesis of Helicobacter pylori-induced mucosa-associated lymphoid tissue (MALT) lymphoma: Analysis of the role of small regulatory RNAs in lymphomagenesis and high grade transformation Duration: 01.11.2010 – 01.11.2013 Nägeli Hanspeter | KLS 01827022006 | CHF 117,700.– Institut für Veterinärpharmakologie und toxikologie, Universität Zürich, Zürich Regulation of nucleotide excision repair activity by protein modifiers Ochsenbein Adrian F. | OCS 01627022005 | CHF 274,300.– Universitätsklinik für medizinische Onkologie, Inselspital, Bern Immunosurveillance of chronic myeloid leukemia in mice Orend Gertraud | OCS 01875022006 | CHF 304,100.– Unité Inserm 682, Institut national de la santé et de la recherche médicale (INSERM), Strasbourg, France Analysis of a potential oncogenic function of tenascin-C and tenascin-W in colon cancer Pabst Thomas | OCS 01833022006 | CHF 249,000.– Universitätsklinik für medizinische Onkologie, Inselspital, Bern The myeloid key transcription factor CEBPA and the pathophysiology of acute myeloid leukemia Pelkmans Lucas | OCS 02111082007 | CHF 198,000.– Institut für molekulare Systembiologie, ETH Zürich, Zürich How focal adhesion kinase (FAK) controls membrane partitioning and endocytosis of cell adhesion components in normal and in cancer cells Peter Matthias | OCS 02189022008 | CHF 229,400.– Institut für Biochemie, ETH Zürich, Zürich Regulation of genome stability by Rtt101p/cullin4-based E3-ubiquitin ligases in yeast and mammalian cells Plückthun Andreas | OCS 02128082007 | CHF 215,400.– Biochemisches Institut, Universität Zürich, Zürich Tumor targeting of ErbB2 with designed ankyrin repeat proteins Pruschy Martin | OCS 02129082007 | CHF 223,100.– Labor für molekulare Radiobiologie, Klinik für RadioOnkologie, UniversitätsSpital Zürich, Zürich Microtubule interference as target for combined cancer therapy with ionizing radiation Radtke Freddy | OCS 01560082004 | CHF 140,600.– UPRAD, Institut suisse de recherche expérimentale sur le cancer (ISREC), Faculté des sciences de la vie, EPF de Lausanne, Lausanne The role of Notch2 in murine epidermis Radtke Freddy | KLS 01840022006 | CHF 346,300.– UPRAD, Institut suisse de recherche expérimentale sur le cancer (ISREC), Faculté des sciences de la vie, EPF de Lausanne, Lausanne The role of Notch1 signalling in acute lymphoblastic T-cell leukaemia (T-ALL) Renner Christoph | OCS 02119082007 | CHF 192,200.– Klinik und Poliklinik für Onkologie, Medizinbereich Innere Medizin – Onkologie, UniversitätsSpital Zürich, Zürich Selective inhibition of intratumoral regulatoy T-cells by antibody-GITR ligand fusion proteins 61
Page 1 and 2:
Cancer Research in Switzerland A pu
Page 3 and 4:
Cancer Research in Switzerland
Page 5 and 6:
Basic biomedical research 55 Cancer
Page 7 and 8:
policy work and was in charge of de
Page 9 and 10:
The main focus of the research fund
Page 11 and 12: gramme research funding decreased b
Page 13 and 14: Table 2 Distribution of funds for i
Page 15 and 16: Funding patient-centred research Pa
Page 17 and 18: value was not clearly discernible.
Page 19 and 20: New organization of the Foundation
Page 21 and 22: The board of the Foundation Cancer
Page 23 and 24: The president of the Scientific Com
Page 25 and 26: Prof. Martin Pruschy, PhD Departmen
Page 27 and 28: Swartz wants to find out how tumour
Page 29 and 30: The scientific and medical research
Page 31 and 32: 3. The original order/sequence of t
Page 33 and 34: As a federation, the Cancer League
Page 35 and 36: List of funded research projects, i
Page 37 and 38: Zippelius Alfred | 2009: CHF 100,00
Page 39 and 40: Kridel Robert | 2010: CHF 100,000.-
Page 41 and 42: Thurgau Cancer League Biotechnologi
Page 43 and 44: Weller Michael | 2010: CHF 65,828.-
Page 45 and 46: manageable funding of individual pr
Page 47 and 48: enhances breast cancer cell motilit
Page 49 and 50: Rüegg Curzio et al. | Tumor-mediat
Page 51 and 52: International Clinical Cancer Resea
Page 53 and 54: in PHIV were shown for Hodgkin’s
Page 55: Zucca Emanuele et al. | Internation
Page 58 and 59: 56 “hierarchical structure” of
Page 60 and 61: 58 the attempt should be made to st
Page 64 and 65: 62 Romero Pedro | OCS 020110220
Page 66 and 67: 64 Beermann Friedrich | In vivo scr
Page 68 and 69: 66 Christofori Gerhard | Podoplanin
Page 70 and 71: 68 Frei Christian | The function of
Page 72 and 73: 70 cell, this novel mechanism serve
Page 74 and 75: 72 Results The induction of viral p
Page 76 and 77: 74 Hübscher Ulrich | Repair of oxi
Page 78 and 79: 76 Methods and experimental approac
Page 80 and 81: 78 of cMyc and/or NMyc and demo
Page 82 and 83: 80 In summary, this work improves o
Page 84 and 85: 82 Pruschy Martin | Microtubule int
Page 86 and 87: 84 Renner Christoph | Selective inh
Page 88 and 89: 86 Goal Here we build on these obse
Page 90 and 91: 88 by TDG prevents efficient downst
Page 92 and 93: 90 To address these questions, we a
Page 94 and 95: 92 Translational relevance The resu
Page 96 and 97: 94 Grünberg Jürgen | KFS 025460
Page 98 and 99: 96 Tschan Mario P. | KFS 0248608
Page 100 and 101: 98 Boyman Onur | Preclinical testin
Page 102 and 103: 100 Constam Daniel | Role of activi
Page 104 and 105: 102 this study we will examine the
Page 106 and 107: 104 Janscak Pavel | Study of the ro
Page 108 and 109: 106 Müller Anne | The molecular pa
Page 110 and 111: 108 Radtke Freddy | The role of Not
Page 112 and 113:
110 Schär Primo | DNA repair, epig
Page 114 and 115:
112 In this project we will investi
Page 116 and 117:
114
Page 118 and 119:
116 and Research). Other financial
Page 120 and 121:
118 be totally unaffordable for aca
Page 122 and 123:
120 Clinical research List of compl
Page 124 and 125:
122 Hunger Robert E. | OCS 02262-08
Page 126 and 127:
124 Clinical research Presentation
Page 128 and 129:
126 Benhattar Jean | Identification
Page 130 and 131:
128 Bertoni Francesco | Genome-wide
Page 132 and 133:
130 Interpretation ESA treatment in
Page 134 and 135:
132 Our results could pave the way
Page 136 and 137:
134 new drugs that specifically tar
Page 138 and 139:
136 slides in two different concent
Page 140 and 141:
138 Conclusions A strong network of
Page 142 and 143:
140 tions introduced to ARE motifs
Page 144 and 145:
142 Müller Beatrice U. | The maste
Page 146 and 147:
144 A novel method was developed fo
Page 148 and 149:
146 (SAKK 35-98) the Swiss Group fo
Page 150 and 151:
148 Timmermann Beate | Prospective
Page 152 and 153:
150 recurrence of the disease, we a
Page 154 and 155:
152 Zucca Emanuele | A prospective
Page 156 and 157:
154 Heinimann Karl | KFS 02489-08-2
Page 158 and 159:
156 Riggi Nicolò | BIL KFS 02717-0
Page 160 and 161:
158 activity at the single cell lev
Page 162 and 163:
160 Our research projects aim at un
Page 164 and 165:
162 Körner Meike | In vitro evalua
Page 166 and 167:
164 Nadal David | Is endemic Burkit
Page 168 and 169:
166 (> 50.000/patient). For their a
Page 170 and 171:
168 Zeller Rolf | Functional analys
Page 172 and 173:
170
Page 174 and 175:
172 area of health services researc
Page 176 and 177:
174 The financing of palliative car
Page 178 and 179:
176 National Strategy for Palliativ
Page 180 and 181:
178 Psychosocial research List of c
Page 182 and 183:
180 Within the patient group, level
Page 184 and 185:
182 Further, the results suggest th
Page 186 and 187:
184 It is in this context that the
Page 188 and 189:
186 Recommendation Female spouses o
Page 190 and 191:
188 Psychosocial research Presentat
Page 192 and 193:
190 rates communication skills rema
Page 195 and 196:
Epidemiological research Epidemiolo
Page 197 and 198:
data from cancer registries. In the
Page 199 and 200:
The importance of cancer registries
Page 201 and 202:
Ess Silvia | Patterns of care and s
Page 203 and 204:
Epidemiological research List of ap
Page 205 and 206:
Impact This work will serve as the
Page 207 and 208:
Thürlimann Beat | Management of br
show all

Cancer Research in Switzerland - Krebsliga Schweiz

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?